Wegovy pen volume: how much liquid is in each injection?

What Wegovy's clinical programme tells us about fixed-volume dosing

The STEP 1 trial, published in the New England Journal of Medicine, studied semaglutide 2.4 mg in adults with obesity over 68 weeks and recorded an average body-weight reduction of around 15%. What the published methodology makes clear is that the 2.4 mg maintenance dose is achieved not by increasing the injection volume but by progressively increasing semaglutide concentration within the same 1.5 ml cartridge that runs across the entire product range. Every pen in the Wegovy titration schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg) delivers 1.5 ml. The 7.2 mg pen, approved by the MHRA on 14 April 2026 as a dedicated single-dose format, follows the same principle: a higher concentration of semaglutide in the same fixed volume. This is standard pharmaceutical engineering for subcutaneous injection devices, and it means the physical experience of injecting does not escalate alongside the dose.

For anyone reading about Wegovy pen volumes in millilitres, this is the key fact: 1.5 ml, consistent across all dose strengths. You may find references to 0.5 ml or 1 ml injection volumes for older formulations of semaglutide, those relate to different presentations and different indications. The licensed Wegovy weight-management pen always delivers 1.5 ml per use.

How fixed volume translates into practical injection experience

Because the volume stays constant, the mechanics of using the pen stay constant too. You press the button, hold it in place while the pen clicks, and the 1.5 ml is delivered. There is no reason to press harder at 2.4 mg than at 0.25 mg, and no reason to expect the injection to take longer. The NHS semaglutide medicines page and the Patient Information Leaflet inside each pack both confirm the correct technique, holding the pen against the skin for the recommended count until the injection window confirms delivery. That confirmation window is worth checking every time; it takes seconds and confirms the full dose has been released rather than partially expelled.

Injection sites are the abdomen, thigh, or upper arm. Rotating sites each week reduces the chance of localised tissue changes. The depth of the needle and the volume entering the subcutaneous layer are identical regardless of which Wegovy pen you are using. If you want a step-by-step walk-through of the process, the guide to using the Wegovy pen covers each stage in order.

The 7.2 mg pen: same principle, new format

The MHRA's April 2026 approval of a dedicated 7.2 mg single-dose pen introduced an auto-dosing mechanism with a built-in covered needle that locks after use. The volume delivered remains within the same design parameters as the rest of the range. This pen is licensed for adults with a BMI of 30 or above, and the titration path to reach 7.2 mg still starts at 0.25 mg, so patients pass through each lower-dose pen before reaching the highest strength. The prescriber oversees each step. Details of the individual Wegovy starter pen and the broader Wegovy treatment overview cover how those earlier stages work in practice.

One practical note on the new pen format: because the needle is pre-set and covered, users do not attach a separate needle tip before injecting, unlike some other injection devices. This matters for disposal, a full sharps container is still required. A 1-litre sharps container is suitable for standard home use and can be collected by most local authorities when full. For context on how Wegovy's injection format compares to other semaglutide products on the market, the page on semaglutide injection products and their licensed indications explains which products are licensed for weight management and which are not.

Eligibility, clinical assessment, and the private route

Wegovy is a prescription-only medicine. A prescriber (not an online form alone) decides whether the treatment is appropriate based on your BMI, health history and current medicines. The licensed threshold is BMI 30 or above, or 27 to 29.9 alongside a weight-related health condition such as high blood pressure or high cholesterol. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

On the NHS, Wegovy is available through specialist weight management services under NICE guidance (TA875), and waiting lists are commonly long. Private treatment through a regulated online pharmacy is the alternative for people who do not meet the current NHS criteria or prefer not to wait. If you are weighing up the cost of Wegovy privately, our pricing page sets out what a single transparent price includes. When you are ready to find out whether treatment is right for you, our prescribers are available to review your consultation the same day it is submitted.

Speak to our prescribers by starting your free consultation.